| [1] |
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. Lancet, 2021, 397(10284): 1577-90. doi:10.1016/s0140-6736(20)32205-4
|
| [2] |
Twarowski B, Herbet M. Inflammatory processes in Alzheimer's disease-pathomechanism, diagnosis and treatment: a review[J]. Int J Mol Sci, 2023, 24(7): 6518. doi:10.3390/ijms24076518
|
| [3] |
Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials[J]. Lancet Neurol, 2022, 21(8): 726-34. doi:10.1016/s1474-4422(22)00168-5
|
| [4] |
Rostagno AA. Pathogenesis of Alzheimer's disease[J]. Int J Mol Sci, 2022, 24(1): 107. doi:10.3390/ijms24010107
|
| [5] |
Bomasang-Layno E, Bronsther R. Diagnosis and treatment of Alzheimer's disease: : an update[J]. Dela J Public Health, 2021, 7(4): 74-85. doi:10.32481/djph.2021.09.009
|
| [6] |
Li SP, Han WF, He QC, et al. Relationship between intestinal microflora and hepatocellular cancer based on gut-liver axis theory[J]. Contrast Media Mol Imaging, 2022, 2022: 6533628. doi:10.1155/2022/6533628
|
| [7] |
Socała K, Doboszewska U, Szopa A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders[J]. Pharmacol Res, 2021, 172: 105840. doi:10.1016/j.phrs.2021.105840
|
| [8] |
O’Riordan KJ, Moloney GM, Keane L, et al. The gut microbiota-immune-brain axis: Therapeutic implications[J]. Cell Rep Med, 2025, 6(3): 101982. doi:10.1016/j.xcrm.2025.101982
|
| [9] |
Lu X, Xue ZY, Qian Y, et al. Changes in intestinal microflora and its metabolites underlie the cognitive impairment in preterm rats[J]. Front Cell Infect Microbiol, 2022, 12: 945851. doi:10.3389/fcimb.2022.945851
|
| [10] |
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication[J]. Front Endocrinol, 2020, 11: 25. doi:10.3389/fendo.2020.00025
|
| [11] |
He M, Wei WQ, Zhang YC, et al. Gut microbial metabolites SCFAs and chronic kidney disease[J]. J Transl Med, 2024, 22(1): 172. doi:10.1186/s12967-024-04974-6
|
| [12] |
Wang YL, Li L, Zhao XD, et al. Intestinal microflora changes in patients with mild Alzheimer's disease in a Chinese cohort[J]. J Alzheimers Dis, 2022, 88(2): 563-75. doi:10.3233/jad-220076
|
| [13] |
Elmas A, Spehar K, Do R, et al. Associations of circulating biomarkers with disease risks: a two-sample Mendelian randomization study[J]. Int J Mol Sci, 2024, 25(13): 7376. doi:10.3390/ijms25137376
|
| [14] |
Bhattacharyya U, John J, Lam M, et al. Circulating blood-based proteins in psychopathology and cognition: a Mendelian randomization study[J]. JAMA Psychiatry, 2025, 82(5): 481-91. doi:10.1001/jamapsychiatry.2025.0033
|
| [15] |
Lv YC, Cheng X, Dong Q. SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study[J]. Cardiovasc Diabetol, 2024, 23(1): 157. doi:10.1186/s12933-024-02255-6
|
| [16] |
Huang SY, Yang YX, Zhang YR, et al. Investigating causal relations between circulating metabolites and Alzheimer's disease: a Mendelian randomization study[J]. J Alzheimers Dis, 2022, 87(1): 463-77. doi:10.3233/jad-220050
|
| [17] |
Tettevi EJ, Simpong DL, Maina M, et al. Antibiotic-induced gut dysbiosis modulates Alzheimer's disease-associated gene expression and protein aggregation in 3xTg-AD mice via the gut–brain axis[J]. Brain Behav, 2025, 15(10): e70946. doi:10.1002/brb3.70946
|
| [18] |
雷雯慧, 高 婕, 徐 鹏, 等. 阿尔茨海默病肠道细菌和真菌菌群结构和组成改变研究[J]. 中国微生态学杂志, 2024, 36(5): 577-83. doi:10.13381/j.cnki.cjm.202405013
|
| [19] |
Loh JS, Mak WQ, Tan LKS, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases[J]. Signal Transduct Target Ther, 2024, 9(1): 37. doi:10.1038/s41392-024-01743-1
|
| [20] |
Qin YW, Havulinna AS, Liu Y, et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort[J]. Nat Genet, 2022, 54(2): 134-42. doi:10.1038/s41588-021-00991-z
|
| [21] |
Karjalainen MK, Karthikeyan S, Oliver-Williams C, et al. Genome-wide characterization of circulating metabolic biomarkers[J]. Nature, 2024, 628(8006): 130-8.
|
| [22] |
Li PS, Wang HY, Guo L, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian random-ization study[J]. BMC Med, 2022, 20(1): 443. doi:10.1186/s12916-022-02657-x
|
| [23] |
Wu J, Li CS, Huang WY, et al. Gut microbiota promote the propagation of pathologic α-syn from gut to brain in a gut-originated mouse model of Parkinson's disease[J]. Brain Behav Immun, 2025, 128: 152-69. doi:10.1016/j.bbi.2025.04.001
|
| [24] |
Yadav S, Raj RG. Parkinson's disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons[J]. Neuroscience, 2025, 581: 1-15. doi:10.1016/j.neuroscience.2025.07.003
|
| [25] |
Yan ZZ, Yang F, Cao JW, et al. Alterations of gut microbiota and metabolome with Parkinson's disease[J]. Microb Pathog, 2021, 160: 105187. doi:10.1016/j.micpath.2021.105187
|
| [26] |
Kalyanaraman B, Cheng G, Hardy M. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications[J]. Redox Biol, 2024, 71: 103092. doi:10.1016/j.redox.2024.103092
|
| [27] |
Aho VTE, Houser MC, Pereira PAB, et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease[J]. Mol Neurodegener, 2021, 16(1): 6. doi:10.1186/s13024-021-00427-6
|
| [28] |
Chen Z, Chen ZY, Jin XL. Mendelian randomization supports causality between overweight status and accelerated aging[J]. Aging Cell, 2023, 22(8): e13899. doi:10.1111/acel.13899
|
| [29] |
Lv XF, Liang FQ, Liu SS, et al. Causal relationship between diet and knee osteoarthritis: a Mendelian randomization analysis[J]. PLoS One, 2024, 19(1): e0297269. doi:10.1371/journal.pone.0297269
|
| [30] |
Liang Z, Zhao L, Lou Y, et al. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study[J]. QJM, 2023, 116(6): 421-8. doi:10.1093/qjmed/hcad048
|
| [31] |
Zhu X, Huang SJ, Kang WY, et al. Associations between polyunsaturated fatty acid concentrations and Parkinson's disease: a two-sample Mendelian randomization study[J]. Front Aging Neurosci, 2023, 15: 1123239. doi:10.3389/fnagi.2023.1123239
|
| [32] |
Ndongo S, Dubourg G, Bittar F, et al. Marseillibacter massiliensis gen. nov., sp. nov., a new bacterial genus isolated from the human gut[J]. New Microbes New Infect, 2017, 16: 30-1. doi:10.1016/j.nmni.2016.12.006
|
| [33] |
Tran VTA, Kang YJ, Kim HK, et al. Oral pathogenic bacteria-inducing neurodegenerative microgliosis in human neural cell platform[J]. Int J Mol Sci, 2021, 22(13): 6925. doi:10.3390/ijms22136925
|
| [34] |
Wu LC, Du LL, Ju QQ, et al. Silencing TLR4/MyD88/NF‑κB signaling pathway alleviated inflammation of corneal epithelial cells infected by ISE[J]. Inflammation, 2021, 44(2): 633-44. doi:10.1007/s10753-020-01363-1
|
| [35] |
Shi J, Wang F, Tang L, et al. Akkermansia muciniphila attenuates LPS-induced acute kidney injury by inhibiting TLR4/NF‑κB pathway[J]. FEMS Microbiol Lett, 2022, 369(1): fnac103. doi:10.1093/femsle/fnac103
|
| [36] |
Wu XY, Wei JJ, Ran W, et al. The gut microbiota-xanthurenic acid-aromatic hydrocarbon receptor axis mediates the anticolitic effects of trilobatin[J]. Adv Sci, 2025, 12(10): 2412234. doi:10.1002/advs.202412234
|
| [37] |
Yu X, Shen GX, Zhang Y, et al. Genetically predicted small dense low-density lipoprotein cholesterol and ischemic stroke subtype: multivariable Mendelian randomization study[J]. Front Endocrinol, 2024, 15: 1404234. doi:10.3389/fendo.2024.1404234
|
| [38] |
Hashemi M, Banerjee S, Lyubchenko YL. Free cholesterol accelerates aβ self-assembly on membranes at physiological concentration[J]. Int J Mol Sci, 2022, 23(5): 2803. doi:10.3390/ijms23052803
|